
Marco Canepa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1946952/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Longitudinal Trajectories of Arterial Stiffness and the Role of Blood Pressure. Hypertension, 2013, 62, 934-941.	2.7	333
2	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. European Journal of Heart Failure, 2018, 20, 879-887.	7.1	138
3	Linking Heart Failure to Cancer. Circulation, 2018, 138, 735-742.	1.6	115
4	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC: Heart Failure, 2018, 6, 452-462.	4.1	94
5	Characteristics, treatments and 1â€year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2018, 20, 100-110.	7.1	86
6	Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1314-1321.	5.3	82
7	Arterial Stiffness and Vitamin D Levels: the Baltimore Longitudinal Study of Aging. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3717-3723.	3.6	80
8	p38 MAPK and JNK Antagonistically Control Senescence and Cytoplasmic p16INK4A Expression in Doxorubicin-Treated Endothelial Progenitor Cells. PLoS ONE, 2010, 5, e15583.	2.5	70
9	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. Oncologist, 2018, 23, 936-942.	3.7	69
10	Testosterone Antagonizes Doxorubicinâ€Induced Senescence of Cardiomyocytes. Journal of the American Heart Association, 2016, 5, .	3.7	62
11	Relationship Between Interâ€Arm Difference in Systolic Blood Pressure and Arterial Stiffness in Communityâ€Đwelling Older Adults. Journal of Clinical Hypertension, 2013, 15, 880-887.	2.0	59
12	Longitudinal Association Between Serum Uric Acid and Arterial Stiffness. Hypertension, 2017, 69, 228-235.	2.7	59
13	Diagnostic and Therapeutic Gaps inÂPatients With HeartÂFailure and ChronicÂObstructive PulmonaryÂDisease. JACC: Heart Failure, 2019, 7, 823-833.	4.1	55
14	The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity. Scientific Reports, 2016, 6, 29994.	3.3	52
15	Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2020, 13, e007230.	3.9	48
16	Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2018, 7, .	3.7	47
17	What can we learn from pulmonary function testing in heart failure?. European Journal of Heart Failure, 2017, 19, 1222-1229.	7.1	46
18	Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial. Cardiology, 2017, 136, 128-137.	1.4	46

#	Article	IF	CITATIONS
19	Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the <scp>ACâ€TIVE</scp> study, an <scp>Italian nationwide survey</scp> . European Journal of Heart Failure, 2022, 24, 1377-1386.	7.1	43
20	Comparison of Clinical Presentation, Left Ventricular Morphology, Hemodynamics, and Exercise Tolerance in Obese Versus Nonobese Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2013, 112, 1182-1189.	1.6	42
21	Contribution of Central Adiposity to Left Ventricular Diastolic Function (from the Baltimore) Tj ETQq1 1 0.784314	rgBT /Ov	verlock 10 Tf 41
22	The association between leptin and depressive symptoms is modulated by abdominal adiposity. Psychoneuroendocrinology, 2014, 42, 1-10.	2.7	39
23	Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 12-18.	3.0	38
24	5â€fluorouracil causes endothelial cell senescence: potential protective role of glucagonâ€like peptide 1. British Journal of Pharmacology, 2017, 174, 3713-3726.	5.4	37
25	Impact of Central Obesity on the Estimation of Carotid-Femoral Pulse Wave Velocity. American Journal of Hypertension, 2014, 27, 1209-1217.	2.0	34
26	Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 86-93.	3.0	34
27	Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly. Heart, 2016, 102, 1087-1094.	2.9	30
28	Comparison of Outcomes in Patients With Nonobstructive, Labile-Obstructive, and Chronically Obstructive Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2015, 116, 938-944.	1.6	29
29	Brugada syndrome and syncope: a practical approach for diagnosis and treatment. Europace, 2021, 23, 996-1002.	1.7	29
30	Sacubitril/valsartan in realâ€life European patients with heart failure and reduced ejection fraction: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 3547-3556.	3.1	29
31	Incidence and risk factors for pacemaker implantation in lightâ€chain and transthyretin cardiac amyloidosis. European Journal of Heart Failure, 2022, 24, 1227-1236.	7.1	28
32	Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure. Heart Failure Reviews, 2016, 21, 539-547.	3.9	27
33	Prevalence, Clinical Correlates, and Functional Impact of Subaortic Ventricular Septal Bulge (from) Tj ETQq1 1 0.7	84314 rgl 1.6	BT ₂ /Overlock
34	Lower Mitochondrial Energy Production of the Thigh Muscles in Patients With Lowâ€Normal Ankleâ€Brachial Index. Journal of the American Heart Association, 2017, 6, .	3.7	23
35	Brugada syndrome and syncope: A systematic review. Journal of Cardiovascular Electrophysiology, 2020, 31, 3334-3338.	1.7	23
36	Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e016309.	3.7	23

MARCO CANEPA

#	Article	IF	CITATIONS
37	Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from The Swedish Heart Failure Registry. International Journal of Cardiology, 2021, 343, 63-72.	1.7	23
38	E/e′ ratio and outcome prediction in hypertrophic cardiomyopathy: the influence of outflow tract obstruction. European Heart Journal Cardiovascular Imaging, 2018, 19, 101-107.	1.2	22
39	Indoxyl Sulfate: A Candidate Target for the Prevention and Treatment of Cardiovascular Disease in Chronic Kidney Disease. Current Drug Targets, 2015, 16, 366-372.	2.1	22
40	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization — the first insight from the AC-TIVE Study. European Journal of Preventive Cardiology, 2022, 29, e173-e177.	1.8	21
41	Thrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effects. International Journal of Cardiology, 2018, 271, 219-227.	1.7	19
42	Clinical application of CMR in cardiomyopathies: evolving concepts and techniques. Heart Failure Reviews, 2023, 28, 77-95.	3.9	19
43	Current patterns of betaâ€blocker prescription in cardiac amyloidosis: an Italian nationwide survey. ESC Heart Failure, 2021, 8, 3369-3374.	3.1	18
44	Vitamin D modulates the association of circulating insulin-like growth factor-1 with carotid artery intima-media thickness. Atherosclerosis, 2014, 236, 418-425.	0.8	17
45	Recurrent and Residual Shunts After Patent Foramen Ovale Closure: Results From a Longâ€Term Transcranial Doppler Study. Journal of Interventional Cardiology, 2015, 28, 600-608.	1.2	17
46	Impact of peak provoked left ventricular outflow tract gradients on clinical outcomes in hypertrophic cardiomyopathy. International Journal of Cardiology, 2017, 243, 290-295.	1.7	17
47	Realâ€world versus trial patients with transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2019, 21, 1479-1481.	7.1	17
48	Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: a network meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 56-64.	3.0	17
49	Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: The ACTUAL study. International Journal of Cardiology, 2021, 329, 144-147.	1.7	17
50	Doxorubicin Impairs the Insulin-Like Growth Factor-1 System and Causes Insulin-Like Growth Factor-1 Resistance in Cardiomyocytes. PLoS ONE, 2015, 10, e0124643.	2.5	16
51	Characteristics of current heart failure patients admitted to internal medicine vs. cardiology hospital units: the VASCO study. Internal and Emergency Medicine, 2020, 15, 1219-1229.	2.0	16
52	Role of bone mineral density in the inverse relationship between body size and aortic calcification: Results from the Baltimore Longitudinal Study of Aging. Atherosclerosis, 2014, 235, 169-175.	0.8	15
53	Long-Term Left Ventricular Remodeling of Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 122, 1924-1931.	1.6	15
54	Correlation between thoracic aorta 18F-natrium fluoride uptake and cardiovascular risk. World Journal of Radiology, 2016, 8, 82.	1.1	15

MARCO CANEPA

#	Article	IF	CITATIONS
55	Sport practice in hypertrophic cardiomyopathy: running to stand still?. International Journal of Cardiology, 2021, 345, 77-82.	1.7	12
56	Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenterÂltalian register. European Heart Journal Open, 2022, 2, .	2.3	11
57	Prevalent cardiac, renal and cardiorenal damage in patients with advanced abdominal aortic aneurysms. Internal and Emergency Medicine, 2016, 11, 205-212.	2.0	10
58	Methods, accuracy and clinical implications of atrial fibrillation detection by cardiac implantable electronic devices. International Journal of Cardiology, 2017, 236, 262-269.	1.7	9
59	Pulse Wave Velocity Testing in the Baltimore Longitudinal Study of Aging. Journal of Visualized Experiments, 2014, , e50817.	0.3	8
60	Cancer in chronic heart failure patients in the GISSIâ€HF trial. European Journal of Clinical Investigation, 2020, 50, e13273.	3.4	8
61	Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 768-776.	3.0	8
62	Modes of death and prognostic outliers in chronic heart failure. American Heart Journal, 2019, 208, 100-109.	2.7	7
63	Clinical characteristics and prognostic impact of atrial fibrillation in patients with chronic heart failure. World Journal of Cardiology, 2016, 8, 647.	1.5	7
64	Frequency, characteristics and prognostic impact of hospital readmissions in elderly patients with heart failure: A population study from 2013 to 2017 in Liguria, Northern Italy. International Journal of Cardiology, 2022, 363, 111-118.	1.7	7
65	From Arterial Stiffness to Heart Failure: Still a Long Way to Go. Journal of the American Heart Association, 2015, 4, .	3.7	6
66	Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia. International Journal of Cardiology, 2018, 255, 215-220.	1.7	6
67	Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure. Internal and Emergency Medicine, 2019, 14, 1083-1090.	2.0	5
68	Testing longitudinal data for prognostication in ambulatory heart failure patients with reduced ejection fraction. A proof of principle from the GISSI-HF database. International Journal of Cardiology, 2020, 313, 89-96.	1.7	5
69	Yield of bone scintigraphy screening for transthyretinâ€related cardiac amyloidosis in different conditions: Methodological issues and clinical implications. European Journal of Clinical Investigation, 2021, 51, e13665.	3.4	5
70	Diagnostic value of ischemia severity at myocardial perfusion imaging in elderly persons with suspected coronary disease. Journal of Cardiovascular Medicine, 2016, 17, 719-728.	1.5	4
71	Use of loop diuretics in chronic heart failure: do we adhere to the <scp>Hippocratian</scp> principle â€~do no harm'?. European Journal of Heart Failure, 2021, 23, 1068-1075.	7.1	4
72	Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation. Journal of Cardiovascular Translational Research, 2019, 12, 514-516.	2.4	3

MARCO CANEPA

#	Article	IF	CITATIONS
73	Letter regarding the article â€~Heart failure with preserved ejection fraction: from mechanisms to therapies' by Lam and colleagues. European Heart Journal, 2019, 40, 703-704.	2.2	3
74	Chronic obstructive pulmonary disease and comorbidities in heart failure: the next frontier of sodium–glucose coâ€transporter 2 inhibitors?. European Journal of Heart Failure, 2021, 23, 644-647.	7.1	3
75	Sometimes they come back. Journal of Cardiovascular Medicine, 2017, 18, 443-446.	1.5	2
76	Data regarding the effects of thrombin and dabigatran-inhibited thrombin on protease-activated receptor 1 and activation of human atrial fibroblasts. Data in Brief, 2018, 19, 925-931.	1.0	2
77	The impossible quest to make cardiac amyloidosis diagnosis easy. European Journal of Clinical Investigation, 2021, 51, e13512.	3.4	2
78	Metabolic and densitometric correlation between atherosclerotic plaque and trabecular bone: an F-Natrium-Fluoride PET/CT study. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 387-396.	1.0	2
79	Usefulness of the MACGIC Score in Predicting the Competing Risk of Non-Sudden Death in Heart Failure Patients Receiving an Implantable Cardioverter-Defibrillator: A Sub-Analysis of the OBSERVO-ICD Registry. Journal of Clinical Medicine, 2022, 11, 121.	2.4	2
80	Using unsupervised learning to determine risk level for left ventricular diastolic dysfunction. , 2014, ,		1
81	T1 mapping with cardiovascular magnetic resonance: an emerging clinical biomarker. Heart, 2017, 103, 326.1-326.	2.9	1
82	Time for an "Atrial-Watchful―Approach for Heart Failure Patients With a Cardiac Implantable Electronic Device. Journal of the American College of Cardiology, 2018, 71, 1187-1188.	2.8	1
83	Supremacy of echocardiography in the diagnostic workup of systemic AL amyloidosis. European Heart Journal, 2020, 41, 3487-3487.	2.2	1
84	Acknowledging the complex puzzle that links heart failure hospitalizations to outcomes. Letter regarding the article †Readmission and death in patients admitted with newâ€onset versus worsening of chronic heart failure: insights from a nationwide cohort'. European Journal of Heart Failure, 2021, 23, 683-683.	7.1	1
85	Frequency, predictors and prognostic impact of implantable cardioverter defibrillator shocks in a primary prevention population with heart failure and reduced ejection fraction. Journal of Cardiovascular Medicine, 2021, 22, 118-125.	1.5	1
86	351 Prevalence and prognostic significance of RV uptake (biventricular uptake) at planar scintigraphy in patients with ATTR cardiac amyloidosis. European Heart Journal Supplements, 2021, 23, .	0.1	1
87	Tailoring risk prediction at the patient level: future perspectives in cardiovascular medicine. International Journal of Cardiology, 2021, 322, 51-52.	1.7	0
88	Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle "do no harm�. European Journal of Heart Failure, 2021, , .	7.1	0
89	465 Unmasking the prevalence of cardiac amyloidosis in the real world: first insights from the phase 2 of active study, an Italian nationwide survey. European Heart Journal Supplements, 2021, 23, .	0.1	0
90	279 Medical treatment with ARNI may reduce indications for primary prevention of sudden cardiac death in heart failure with reduced ejection fraction: insights from discover-ARNI, a multicentre Italian register. European Heart Journal Supplements, 2021, 23, .	0.1	0

#	Article	IF	CITATIONS
91	633â€∫Efficacy of additional medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis. European Heart Journal Supplements, 2021, 23, .	0.1	0
92	266 Deformation imaging by strain in chronic heart failure over sacubitril–valsartan: a multicentre echocardiographic registry (discover)—ARNI. European Heart Journal Supplements, 2021, 23, .	0.1	0